Elevation Oncology, Inc. (ELEV) has disclosed a new risk, in the Debt & Financing category.
Elevation Oncology, Inc. is facing a financial risk linked to its pre-funded warrants issued in June 2023, which could lead to notable stockholder dilution without providing substantial additional capital to the company. The potential exercise of these warrants for a mere $0.0001 per share, and the option for a cashless transaction, means that Elevation may not gain any significant funding from this process. The resulting issuance of a large volume of shares could considerably dilute current stockholder value and, if these shares hit the market, could depress the stock’s market price. This dilution and potential sell-off pose a substantial risk to Elevation’s financial stability and share value.
The average ELEV stock price target is $7.00, implying 55.56% upside potential.
To learn more about Elevation Oncology, Inc.’s risk factors, click here.
